| Title: |
State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (MOUD) and MOUD Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States. |
| Authors: |
Yarbrough, Courtney R.1 (AUTHOR) courtney.yarbrough@emory.edu, Cooper, Hannah L.F.2 (AUTHOR), Beane, Stephanie2 (AUTHOR), Haardörfer, Regine2 (AUTHOR), Ibragimov, Umed2 (AUTHOR), Haley, Danielle F.3 (AUTHOR), Linton, Sabriya4 (AUTHOR), Landes, Sarah2 (AUTHOR), Lewis, Rashunda5 (AUTHOR), Sionean, Catlainn5 (AUTHOR), Cummings, Janet R.1 (AUTHOR) |
| Source: |
Substance Use & Misuse. 2025, Vol. 60 Issue 4, p531-541. 11p. |
| Subject Terms: |
*MEDICAID law, *METHADONE treatment programs, *HEALTH services accessibility, *CROSS-sectional method, *INTRAVENOUS drug abuse, *INSURANCE, *RESEARCH funding, *HEALTH policy, *HEALTH insurance, *NARCOTICS, *BUPRENORPHINE |
| Geographic Terms: |
UNITED States |
| Abstract: |
Background: People who inject drugs (PWID) are especially vulnerable to harms from opioid use disorder (OUD). Medications for OUD (MOUD) effectively reduce overdose and infectious disease transmission risks. Objective: We investigate whether state Medicaid coverage for methadone and buprenorphine is related to past-year MOUD use among PWID using cross-sectional, multilevel analyses with individual-level data on PWID from the Centers for Disease Control and Prevention's 2018 National HIV Behavioral Surveillance. The sample included 8,142 PWID aged 18-64 who reported daily opioid use from 22 U.S. metropolitan areas. Our outcome was any self-reported MOUD use in the past 12 months. Exposures were state Medicaid coverage and prior authorization requirements for methadone and buprenorphine. We interacted these exposures with PWID race/ethnicity, insurance status, and spatial access to treatment and harm reduction resources. Results: Compared with PWID in states without Medicaid methadone coverage, odds of past-year MOUD use were 73% (p<0.05) higher among PWID in states with methadone coverage requiring prior authorization and 80% (p<0.05) higher among PWID in states with coverage without prior authorization. Insured PWID were twice as likely to report MOUD use than uninsured PWID, with no statistically significant differences between Medicaid versus other insurance. Medicaid prior authorization requirements for buprenorphine were not significantly associated with MOUD use. Non-Hispanic Black PWID were significantly less likely to use MOUD than non-Hispanic White and Hispanic PWID. Conclusions: State Medicaid methadone coverage was strongly associated with higher odds that PWID utilized MOUD, suggesting that expanding methadone insurance coverage could improve MOUD treatment in a vulnerable population. [ABSTRACT FROM AUTHOR] |
|
Copyright of Substance Use & Misuse is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
